Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02477826 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,747
- Enrollment target
NCT02477826 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 2,747 participants.
The verdict
NCT02477826, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,747 participants
- Enrollment target
Study Summary
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,747 participants |
| Start Date | 2015-08-05 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02477826
The ClinicalTrials.gov registry entry for NCT02477826 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,747 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02477826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02477826 about?
NCT02477826 is a clinical study titled "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
What is the current status of trial NCT02477826?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,747 participants. The study started on 2015-08-05. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT02477826?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02477826?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.